There is another revolution that is waiting to happen: one in how we get orphan drugs to patients who need them and help them stay on track with treatment.
Five things big pharma can learn from the rare-disease community
Incentives aren’t the only reason orphan drugs are a success. More important are the lessons companies have learned about patients, social media and support.